Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;18(3):15.
doi: 10.1007/s11864-017-0460-6.

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?

Peter Johnson  1 , Jemma Longley  2
Affiliations
Review

Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?

Peter Johnson et al. Curr Treat Options Oncol. 2017 Mar.

Abstract

The choice of treatment for advanced Hodgkin's lymphoma has traditionally been made using an assessment of the baseline risk factors and a judgement of the balance between efficacy and toxicity for the group in question. The use of functional imaging with 2-(18F)-fluoro-2-deoxy-D-glucose (FDG)-positron emission tomography (PET) early in the course of therapy offers a way to make treatment better adjusted to the most important feature of Hodgkin's lymphoma: the response to therapy. Recent studies have shown that excellent results can be achieved by using early FDG-PET to modulate therapy, with escalation for those with an unsatisfactory response and treatment reduction for those with the most chemosensitive disease. The results of these trials indicate that response-adapted therapy should now become part of the standard approach to care, offering opportunities to improve the results further by indicating those subgroups in need of new approaches such as the emerging antibody-based treatments.

Keywords: Chemotherapy-related toxicity; FDG-PET; Hodgkin’s lymphoma; Response-adapted therapy.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Peter Johnson has received compensation from Millennium (Takeda Oncology) and Bristol-Myers Squibb for service as a consultant.

Jemma Longley declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Figures

Fig. 1
Fig. 1
Comparison of initial treatment approaches in RATHL and LYSA trials.
See this image and copyright information in PMC

References

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Engert A, Diehl V, Franklin J, et al. Escalated-dose BEACOPP in the treatment of patients with advanced stage Hodgkin’s lymphoma: 10 years of follow up of the GHSG HD9 study. J Clin Oncol. 2009;27(27):4548–4554. doi: 10.1200/JCO.2008.19.8820. - DOI - PubMed
    1. Mounier N, Brice P, Bologna S, et al. ABVD (8 cycles) vs. BEACOPP (4 escalated cycles = > 4 baseline): final results in stage III–IV low-risk Hodgkin lymphoma (IPS 0-2) of the LYSA H34 randomized trial. Ann Oncol. 2014;25(8):1622–1628. doi: 10.1093/annonc/mdu189. - DOI - PubMed
    1. Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long term cause specific mortality of patients treated for Hodgkin’s disease. JCO. 2003;21(18):3431–3439. doi: 10.1200/JCO.2003.07.131. - DOI - PubMed
    1. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97(19):1428–1437. doi: 10.1093/jnci/dji290. - DOI - PubMed
    1. Andrea K. Current survivorship recommendations for patients with Hodgkin lymphoma: focus on late effects. Blood. 2014;124:3373–3379. doi: 10.1182/blood-2014-05-579193. - DOI - PubMed

LinkOut - more resources